Drug Treatment for Shock-Refractory Pediatric Pulseless VT/VF
For pediatric pulseless ventricular tachycardia or ventricular fibrillation that does not respond to defibrillation, either amiodarone or lidocaine may be administered as antiarrhythmic therapy, with epinephrine given after 2 defibrillation attempts. 1
Medication Algorithm for Shock-Refractory VF/pVT
First-Line: Epinephrine
- Timing: Administer epinephrine after 2 attempts at defibrillation (or sooner if rapid defibrillation is not possible) 1
- Dosing interval: Continue epinephrine every 3-5 minutes until return of spontaneous circulation (ROSC) 1
- Route: IV or IO preferred over endotracheal administration 1
Antiarrhythmic Therapy: Amiodarone OR Lidocaine
Both agents are considered equivalent options for shock-refractory VF/pVT in pediatrics 1, 2:
- Amiodarone: Traditional first choice based on adult extrapolation
- Lidocaine: May be considered equally effective
The 2025 AHA/AAP guidelines explicitly state that "either amiodarone or lidocaine may be considered" with a Class 2b recommendation 1, 2. This represents equipoise between the two agents.
Evidence Supporting Equipoise Between Antiarrhythmics
The most recent pediatric-specific evidence demonstrates no significant difference in outcomes between lidocaine and amiodarone:
A 2020 propensity-matched study of 180 pediatric in-hospital cardiac arrest patients found no difference in ROSC (RR 0.99), 24-hour survival (RR 1.02), survival to discharge (RR 1.01), or favorable neurological outcome (RR 0.65) between lidocaine and amiodarone 3
An earlier 2014 observational study suggested lidocaine was associated with improved ROSC (adjusted OR 2.02) and 24-hour survival (adjusted OR 1.66), though not survival to discharge, while amiodarone showed no association with improved outcomes 4
Clinical interpretation: The more recent and methodologically stronger propensity-matched study 3 supersedes the earlier observational data 4, supporting the guideline recommendation that either agent is acceptable.
Medications NOT Recommended Routinely
Sodium Bicarbonate
- Not recommended for routine use during pediatric cardiac arrest (Class 3: No Benefit) 1, 2
- Exception: May be used in special circumstances including sodium channel blocker toxicity or hyperkalemia
- Meta-analyses show lower survival to hospital discharge with bicarbonate administration 2
Calcium
- Not recommended for routine use during pediatric cardiac arrest (Class 3: No Benefit) 1, 2
- Exception: May be used for hypocalcemia, calcium channel blocker overdose, or hyperkalemia
Critical Pitfalls to Avoid
Delaying defibrillation for medications: Defibrillation takes priority over drug administration in shockable rhythms. Epinephrine should not delay shock delivery 1
Using endotracheal route when IV/IO available: Due to limited transalveolar absorption and poor pulmonary blood flow during CPR, IV/IO routes are strongly preferred 1, 2
Administering high-dose epinephrine: Routine use of high-dose epinephrine is not recommended 5
Choosing between amiodarone and lidocaine based on perceived superiority: The evidence shows equivalence, so choice should be based on availability and institutional familiarity 3
Practical Implementation
Vascular access: Establish IV or IO access rapidly. IO access is safe, effective, and often faster in pediatric cardiac arrest 1. Choose the route that provides the most timely medication delivery based on available resources and provider expertise.
Continuous CPR during drug administration: With an advanced airway in place, chest compressions should continue at 100/minute without pauses, while ventilations are delivered at 8-10 breaths/minute (approximately every 6-8 seconds) 5